PLUS1
Best deals to access real time data! |
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
CHART Trader
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Immuron Ltd | IMRN | NASDAQ | Depository Receipt |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 3.41 | 0.00 | 0.00 | 0.00 | 3.41 | 04:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.01 | 6.00 | 5.99 | 99.83% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | 0.00 | USD |
Immuron Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | |
|---|---|---|---|---|---|
| 15.07M | 4.42M | -3.01M | -0.90 | - | 4.42M |
| Dividends Per Share | Dividend Yield | ||||
|---|---|---|---|---|---|
| - | - | 0.00% | - | - |
News Immuron
| Date | Time | Source | Heading |
|---|---|---|---|
| 10/17/2019 | 06:07 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 10/15/2019 | 06:48 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 10/14/2019 | 07:30 | GlobeNewswire Inc. | Immuron North American Q1 Sales Up 111% YoY |
| 10/04/2019 | 06:13 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 10/02/2019 | 09:00 | GlobeNewswire Inc. | New U.S. Department of Defense Research Collaboration with.. |
| 10/02/2019 | 06:13 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 9/04/2019 | 06:07 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
IMRN Historical
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's lead product candidate, IMM-124E, is a proprietary immunomodulator agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products. |
